<DOC>
	<DOCNO>NCT00232882</DOCNO>
	<brief_summary>Angiotensin receptor antagonist ( ARA ) , beta-blockers diuretic seem confer equivalent cardiovascular protection hard outcomes clinical trial ( beta blocker inferior ) . These result may explain difference effect sympathetic activity , oxidative stress , inflammation renin angiotensin system activation . How diuretic addition first line therapy ARAs beta-blockers modulate neurohumoral hemodynamic parameter well understood . The main hypothesis study ARA ( candesartan ) combine diuretic increase sympathetic activity much beta blocker ( atenolol ) . Secondary hypothesis similar nature relate hemodynamic parameter , oxidative stress marker , inflammatory marker , renin angiotensin system . The main objective study ass compare effect candesartan atenolol combination low dose diuretic therapy autonomic nervous system , hemodynamic parameter , oxidative stress , inflammatory marker , renin-angiotensin system . Protocol sponsor Astra Zeneca canada</brief_summary>
	<brief_title>Pharmacodynamic Influences Candesartan , Atenolol , Hydrochlorothiazide Drug Combinations Hypertensive Patients .</brief_title>
	<detailed_description>INTRODUCTION . Three large clinical trial ( STOP-2 , HOPE , LIFE ) { Hansson , Lindholm , et al . 1999 } { Dahlof , Devereux , et al . 2002 } { Yusuf , Sleight , et al . 2000 } suggest drug specifically inhibit renin angiotensin system ( RAS ) ACE inhibitor Angiotensin Receptor Antagonists ( ARA ) blood pressure-independant cardiovascular protecting effect . In recent study , LIFE trial , Losartan-based therapy superior atenolol-based therapy hypertensive patient leave ventricular hypertrophy { Dahlof , Devereux , et al . 2002 } . Very recently , ALLHAT mega-trial suggest diuretic good ACE inhibitor cardiovascular protection hypertensive patient { Major outcome moderately hypercholesterolemic , hypertensive patient randomize pravastatin v usual care : The Antihypertensive Lipid-Lowering Treatment Prevent Heart Attack Trial ( ALLHAT-LLT ) } . These apparently conflict result underline mechanisms cardiovascular protection well understood . ARAs { Balt , Mathy , et al . 2001 } { Moreau , Richer , et al . 1993 } sympathoinhibitory property beta-blockers induce small counterregulatory activation sympathetic system { Lijnen , Amery , et al . 1979 } { Sundlof , Wallin , et al . 1983 } { van den Meiracker , Man 't Veld AJ , et al . 1988 } .We show recently telmisartan prevents increase NE normally associate reduction BP report diuretic tend stimulate sympathetic system { Fernandez , Snedden , et al . 1987 } { Lake , Ziegler , et al . 1979 } . It suggest superiority ARAs could due unique effect autonomic nervous system . Angiotensin II receptor antagonism also decrease oxidative stress induce angiotensin II aldosterone { de Cavanagh , Ferder , et al . 1999 } { Hornig , Landmesser , et al . 2001 } { Onozato , Tojo , et al . 2002 } .We also show telmisartan decrease plasma aldosterone therefore decrease oxidative stress associate reduction aldosterone Hydrochlorothiazide beta-blockers show antioxidative property { Welch &amp; Wilcox 2001 } { Taddei , Virdis , et al . 2001 } . It possible oxidative stress partly explain difference pharmacological agent . Patients include high blood pressure clinical trial randomize therapeutic strategy meaning step care approach take . Hypertensive patient frequently need one drug appropriate blood pressure control . Consequently , half study patient trial end take one drug study . First step therapy definition prescribe study subject second third step therapy well define . In HOPE trial , ramipril add top usual treatment . Most patient include HOPE , LIFE , STOP-2 ALLHAT take least one antihypertensive drug , frequently thiazide diuretic . Though result report ACE inhibitor ARA base , mostly reflect mix single drug multiple drug therapy . Whether beneficial effect ARAs beta-blockers modulate thiazide diuretic presently unknown . We design parallel study primarily assess difference ARAs , diuretics beta-blockers . The simultaneously measure parameter reflect renin-angiotensin system activity , sympathetic activity , oxidative stress systemic inflammation . Secondarily , study ass effect ARA-diuretic B-blocker-diuretic combination parameter . Results study help understand result previously mention clinical trial . The forced titration monotherapy combination therapy allow u measure influence drug addition clinically significant parameter . The simultaneous assessment renin-angiotensin system activity , sympathetic activity , oxidative stress systemic inflammation allow u observe baseline pharmacologically-induced association . It also probable result study direct clinical influence high blood pressure therapeutic strategy . Physicians treat hypertension frequently choose increase drug dos maximum add new drug . It presently unknown one strategy offer benefit . This study provide physician clue expect benefit approach . GOALS To assess compare effect candesartan atenolol combine low dose diuretic therapy autonomic nervous system , oxidative stress , inflammatory marker , renin-angiotensin system . To assess compare effect candesartan atenolol low dose diuretic therapy autonomic nervous system , inflammatory marker , oxidative stress , inflammatory marker , renin angiotensin system . PRIMARY OBJECTIVE : 1 . To measure compare effect candesartan 16 mg + HCT 12.5 mg , candesartan 16 mg + HCT 25.0 mg , atenolol 100 + 12.5 mg noradrenalin release 4h post-dose , trough , 10 minute stand . SECONDARY OBJECTIVES : 1 . To measure compare effect candesartan 16 mg + HCT 12.5 mg , candesartan 16 mg + HCT 25.0 mg , atenolol 100 + 12.5 mg : 1. frequency power spectral analysis 4h post-dose , 10 minute stand . 2. oxidative stress , inflammatory marker adhesion molecule 4h post-dose . 3. renin , aldosterone angiotensin II release/production 4h post-dose trough . 4 . Insulin glucose plasma concentration 2 . To measure compare influence HCT 25 mg , candesartan 16 mg , atenolol 100 mg monotherapy : 1. noradrenalin release 4h post-dose , trough , 10 minute stand . 2. frequency power spectral analysis 4h post-dose , 10 minute stand . 3. oxidative stress , inflammatory marker adhesion molecule 4h post-dose . 4. renin , aldosterone angiotensin II release/production 4h post-dose trough . 5 . Insulin glucose plasma concentration DESIGN Prospective , randomize , open label , 3 arm , 2 period parallel study precede placebo run period non-diabetic patient essential hypertension . Titration period : introduction hydrochlorothiazide ( 12.5 mg daily ) , atenolol ( 50 mg daily ) , candesartan ( 8 mg daily ) diuretic , beta-blocker angiotensin receptor blocker group respectively . First study period ( 4 week ) , comparison hydrochlorothiazide 25 mg , atenolol 100 mg , candesartan 16mg . Second study period ( 4 week ) , comparison hydrochlorothiazide 25 mg + candesartan 16 mg , atenolol 100 mg + HCT 12.5 mg , candesartan 16mg + HCT 12.5 mg . Measurement study parameter trough , 4h post-dose 10 minute stand placebo study period . MEASURED STUDY PARAMETERS 1 . Blood pressure 2 . 24h blood pressure 3 . Spectral analysis heart rate ( LF , HF , LF/HF ) 4 . Plasma 1. renin 2. aldosterone 3. angiotensin II 4. catecholamine 5 . 8-epi-isoprostane 6 . Thiobarbituric acid reactive substance ( TBARS ) 7. nitrotyrosine 8. interleukin 18 9 . E selectine 10 . C reactive protein 11 . Insulin 12. glucose 5 . Urine 1 . 8-epi-isoprostane 2. sodium concentration 3. creatinine concentration Protocol Sponsored Astra Zeneca Canada</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
	<criteria>1 . Mild moderate essential hypertension define morning mean DBP *90 mmHg * 109 mm Hg , mean SBP * 200 mm H two consecutive visit ( Visits 2 3 ) twotofour week placebo runin period , 2 . Ability provide write informed consent . 1 . Any woman surgically sterile menopausal : 1. positive urine pregnancy test screening ( Visit 1 ) baseline ( Visit 3 ) 2. breast feeding 2 . Premenopausal woman ( last menstruation &lt; 1 year prior start runin period ) : 1. surgically sterile ; and/or 2. childbearing potential NOT practice acceptable mean birth control . 3 . Known suspected secondary hypertension . 4 . Known reversible nonreversible obstructive lung disease ( e.g . asthma COPD ) . 5 . Hepatic and/or renal dysfunction define follow laboratory parameter : 1 . ALT AST great 2.0 time upper limit reference range ; 2 . Serum creatinine great 150 umol/L . 6 . Uncorrected volume depletion . 7 . NYHA functional class CHF IIIIV ( Refer Appendices ) . 8 . Coronary heart disease need pharmacological therapy . 9 . Stroke within precede six month . 10 . PTCA within precede three month . 11 . History angioedema . 12 . Clinically significant sinus bradycardia 55 beats/min . randomization . 13 . Sustained ventricular tachycardia , atrial fibrillation , clinically relevant cardiac arrhythmia determine clinical Investigator . 14 . Second third degree AV block , leave bundle branch block clinically relevant conduction abnormality determine clinical Investigator . 15 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve . 16 . Administration digoxin . 17 . Patients fast glucose &gt; 7.0 . 18 . Use antihypertensive agent diuretic , ACE inhibitor , angiotensin II antagonist , * blocker , *blockers , calcium channel antagonist , direct vasodilator stop trial . 19 . Administration nonantihypertensive medication know affect blood pressure ( e.g. , oral corticosteroid , MAO inhibitor , nitrate ) time trial . 20 . Chronic use salt substitute contain potassium chloride ; potassium supplement ; extreme dietary restriction . 21 . Uncorrected sodium depletion define serum sodium level le 135 mEq/L . 22 . Clinically significant hyperkalemia define serum potassium level great 5.2 mEq/L . Clinically significant hypokalemia define serum potassium level le 3.0 mEq/L . 23 . Patients receive investigational therapy within one month signing informed consent form . 24 . Known hypersensitivity component candesartan , atenolol hydrochlorothiazide . 25 . Any clinical condition , opinion principal Investigator , would allow safe completion protocol safe administration trial medication . 26 . Known allergy sulfa heparin 27 . Blood donation precede 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>Antihypertensive drug</keyword>
	<keyword>Clinical Pharmacology</keyword>
	<keyword>Autonomic nervous system</keyword>
	<keyword>Renin angiotensin system</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Inflammatory marker</keyword>
</DOC>